At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
E2007 (perampanel) +1 moredrug
Likely dose
E2007 (perampanel) 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Tolerability Titration Study To Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
In Brief
A Phase 2 clinical trial evaluating E2007 (perampanel) and Placebo for Neuralgia. Completed, enrolled 146 participants across 47 sites in 2 countries.
Detailed Summary
The purpose of the study is to determine the efficacy and safety of Perampanel (E2007) in patients with Post-Herpetic Neuralgia (PHN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionDec 2008
Study CompletionMar 2009
TodayJul 2026
First PostedJan 14, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2008
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.5 years ago
Interventions
E2007 (perampanel)drug
2 mg titrated up to 8 mg maximum; taken once daily.
Placebodrug
2 mg titrated up to 8 mg maximum; taken once daily.